Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer

ConclusionRelugolix suppressed testosterone and was generally well tolerated when given with concomitant CV agents.Trial RegistrationClinical Trial ID NCT03085095.Prior Presentation Data presented at 15th Annual Genitourinary Cancers Symposium; February 17 –19, 2022, San Francisco, CA, USA [Abstract 101, Poster board E11]. The published abstract from this presentation can be found athttps://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.101.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research